Recurrent squamous cell carcinoma of the head and neck
Clinical trials for Recurrent squamous cell carcinoma of the head and neck explained in plain language.
Never miss a new study
Get alerted when new Recurrent squamous cell carcinoma of the head and neck trials appear
Sign up with your email to follow new studies for Recurrent squamous cell carcinoma of the head and neck, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Re-irradiation plus cetuximab targets head and neck tumors that return
Disease control CompletedResearchers are testing whether combining cetuximab, a drug that blocks tumor growth, with stereotactic body radiation therapy can help patients whose head and neck cancer has returned after earlier radiation and cannot be removed by surgery. The trial enrolls about 45 people wit…
Matched conditions: RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase 2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Drug combo aims to stall head and neck Cancer's return
Disease control CompletedThis phase 2 trial investigates whether combining two drugs—RAD001 (everolimus) and erlotinib (Tarceva)—can help control recurrent squamous cell carcinoma of the head and neck. The study enrolls adults whose cancer has returned after platinum-based chemotherapy. Participants take…
Matched conditions: RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control CompletedThis study tested a combination of two drugs, duvelisib and docetaxel, in 26 people with head and neck cancer that had returned or spread and could not be cured. The goal was to see if the combination could shrink tumors or slow the disease. The approach aims to control the cance…
Matched conditions: RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase 2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug shows promise for tough head and neck cancers
Disease control CompletedThis study tested an experimental drug called ozuriftamab vedotin in 42 people with head and neck cancer that returned or spread. The goal was to see if the drug could shrink tumors and to check for side effects. Participants received the drug alone or with other treatments, and …
Matched conditions: RECURRENT SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
Phase 2 • Sponsor: BioAtla, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC